Xeris Biopharma Holdings, Inc. XERS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $12.01M+2,068% | $554K+104% | -$15.64M+51.1% | -$32M+29.0% | -$45.08M+17.8% | ||
| $1.34M+1.7% | $1.31M+1.7% | $1.29M+2.5% | $1.26M+3.6% | $1.22M-0.9% | ||
| $22.06M-1.4% | $22.37M+8.1% | $20.69M+4.4% | $19.81M+4.1% | $19.04M+3.7% | ||
| $3.36M+1.4% | $3.31M+1.3% | $3.27M0.0% | $3.27M0.0% | $3.27M+9.0% | ||
| —— | —— | —— | —— | —— | ||
| $14.82M-23.2% | $19.29M+4.7% | $18.41M+19.8% | $15.38M+52.7% | $10.07M+14.6% | ||
| $119K+272% | -$69K+98.1% | -$3.57M— | —— | —— | ||
| —— | —— | —— | —— | -$3.81M-204% | ||
| -$2.05M-151% | $3.99M+332% | -$1.72M-11.1% | -$1.54M-200% | -$515K+52.0% | ||
| —— | $0-100% | $20.75K-50.0% | $41.5K-33.3% | $62.25K-25.0% | ||
| —— | —— | $3.66M— | —— | —— | ||
| $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | ||
| $582K+8.4% | $537K+8.5% | $495K+7.4% | $461K-7.1% | $496K-10.6% | ||
| -$1.66M-5.2% | -$1.58M— | —— | —— | —— | ||
| $48.53M+69.5% | $28.63M+234% | $8.58M+147% | -$18.15M+36.7% | -$28.68M+26.4% | ||
| -$1.01M-44.8% | -$696K-107% | $9.65M— | —— | —— | ||
| $7.56M-34.7% | $11.58M+9.9% | $10.54M— | —— | —— | ||
| $19.9M+82.9% | $10.88M+14.5% | $9.5M+4.3% | $9.11M+9.7% | $8.3M+122% | ||
| —— | —— | —— | —— | -$2.08M-106% | ||
| $53.21M+35.3% | $39.32M+21.9% | $32.26M+1,943% | $1.58M+136% | -$4.35M-207% | ||
| $32.47M+19.7% | $27.12M+3.5% | $26.19M-17.4% | $31.72M+24.6% | $25.45M-5.6% | ||
| $3.36M+1.4% | $3.31M+1.3% | $3.27M0.0% | $3.27M0.0% | $3.27M+9.0% | ||
| $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | ||
| —— | —— | —— | —— | $4.29M-12.3% | ||
| —— | —— | $25.93M+131% | $11.24M+118% | $5.16M+31.6% | ||
| -$1.66M-5.2% | -$1.58M— | —— | —— | —— | ||
| —— | —— | $3.66M— | —— | —— | ||
| $582K+8.4% | $537K+8.5% | $495K+7.4% | $461K-7.1% | $496K-10.6% | ||
| -$1.01M-44.8% | -$696K-19.4% | -$583K+2.7% | -$599K+16.5% | -$717K+17.4% | ||
| -$1.66M-5.2% | -$1.58M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $15.15M+375% | $3.19M— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Xeris Biopharma Holdings, Inc. generate?
- Xeris Biopharma Holdings, Inc. (XERS) generated $48.5M in operating cash flow over the trailing twelve months.
- Where does Xeris Biopharma Holdings, Inc.'s cash flow data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
